Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 11, 2005, Pages 1157-1164

  Foruny, José R ^a   Blázquez, Javier ^a   Moreno, Ana ^a   Bárcena, Rafael ^a   Gil Grande, Luis ^a   Quereda, Carmen ^a   Pérez Elías, Maria J ^a   Moreno, Javier ^a   Sánchez, Juan ^a   Muriel, Alfonso ^a   Rodriguez Sagrado, Miguel A ^a   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Hepatitis C virus cirrhosis; Hypersplenism; Partial splenic embolization; Peg IFN ribavirin; Thrombocytopenia

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTHROMBIN; RIBAVIRIN;

ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD TOXICITY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG USE; EVALUATION; FEMALE; HEALTH CENTER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERSPLENISM; LEUKOCYTE; LIVER CIRRHOSIS; MALE; NEUTROPENIA; PARTIAL SPLENIC EMBOLIZATION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPAIN; THROMBOCYTE;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; EMBOLIZATION, THERAPEUTIC; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERSPLENISM; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 27344454353     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200511000-00002     Document Type: Article

References (43)

1. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
2. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society Expert Panel Consensus Conference on liver transplantation and hepatitis C. Liver Transplant 2003; 9 (suppl 3):S1-S9.
3. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transplant 2003; 9 (suppl 3):S90-S92.
4. Tabor E. Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses. Dig Liver Dis 2003; 35: 297-305.
5. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53:425-430.
6. Heathcote EJ. Treatment considerations in patients with hepatitis C and cirrhosis. J Clin Gastroenterol 2003; 37:395-398.
7. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004; 4 (suppl 1): S31-S38.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al., and the PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
9. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (suppl 1):S237-S244.
10. Maddrey WC. Safety of combination interferon alfa 2-b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19(suppl 1):67-75.
11. Dieterich DT, Spivak JL. Hématologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 533-541.
12. Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002; 35:1281-1282.
13. Dieterich DT, Wassermen R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491-2499.
14. Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42:907-912.
15. Hepatitis Resource Network. Management of side effects in hepatitis C treatment. 2001. Available at: http://www.h-r-n.org/provider/algorithms/ hcvalgo1011.pdf. Accessed: 19 February 2005.
16. Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadoulos N, Burgess A, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 2003; 21:3158-3167.
17. Bai CM, Xu GX, Zhao YQ, Han SM, Shan YD. A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2004; 26:437-441.
18. Sangro B, Bilbao I, Herrero I, Corella C, Longo J, Beloqui O, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993; 18:309-314.
19. Tajiri T, Onda M, Yoshida H, Mamada Y, Taniai N, Kumazaki T. Long-term hematological and biochemical effects of partial splenic embolization in hepatic cirrhosis. Hepatogastroenterology 2002; 49:1445-1448.
20. Moreno A, Bárcena R, Blázquez J, Quereda C, Gil-Grande L, Sánchez J, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV-HCV patients prior to peg-interferon and ribavirin. Antiviral Ther 2004; 9:1027-1030.
21. Bárcena R, Gil-Grande L, Moreno J, Foruny JR, Oton E, Garcia M, et al. Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin. Transplantation 2005; 79:1634-1635.
22. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
23. Fried MW, Schiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 26:975-982.
24. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
25. Torriani FJ, Rodriguez-Torres M, Rockstroh J, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al., and the APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
26. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al., and the ANRS HCO2 RIBAVIC Study Team. Pegylated-interferon-alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized trial. JAMA 2004; 292: 2839-2848.
27. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28:1687-1695.
28. Noguchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 1995; 22:1682-1688.
29. Hidaka H, Kokubu S, Saigenji K, Isobe Y, Maeda T. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res 2002; 23: 265-273.
30. Owman T, Lunderquist A, Alwmark A, Borjesson B. Embolization of the spleen for treatment of splenomegaly and hypersplenism in patients with portal hypertension. Invest Radiol 1979; 14:457-464.
31. Janssen HLA, Wijnhoud A, Haagsma EB, van Uum SHM, van Nieuwkerk CMJ, Adang RP, et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001; 49:720-724.
32. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andréa G, et al. Inherited coagulation disorder in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31:345-348.
33. Mukaiya M, Hirata K, Yamashiro K, Katsuramaki T, Kimura H, Denno R. Changes in portal hemodynamics and hepatic function after partial splenic embolization (PSE) and percutaneous transhepatic obliteration (PTO). Cancer Chemother Pharmacol 1994; 33 (suppl):S37-S41.
34. Winslow ER, Brunt LM, Drebin JA, Soper NJ, Klingensmith ME. Portal vein thrombosis after splenectomy. Am J Surg 2002; 184:631-636.
35. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, lannaccone L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40:736-741.
36. Amitrano A, Guardascione MA, Brancaccio V, lannaccone L, Ames PR, Balzano A. Portal and mesenteric venous thrombosis in cirrhotic patients. Gastroenterology 2002; 123:1409-1410.
37. Romero-Gomez M, Gutierrez-Tous R, Delgado D. Anticoagulation therapy for recent portal vein thrombosis in a patient with liver cirrhosis suffering from variceal rebleeding. Gastroenterology 2002; 122:2095.
38. Everson GT, Trotter JF, Kugelmas M. Long-term outcomes of patients with the LADR protocol (low dose accelerating-dose regimen) [Abstract]. Hepatology 2002; 36:297A.
39. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389-396.
40. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-F25.
41. Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-593.
42. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transplant 2003; 9:905-915.
43. Murata K, Shiraki K, Takase K, Nakano T, Tameda T. Long term follow-up for patients with liver cirrhosis after partial splenic embolization. Hepato-Gastroenterology 1996; 43:1212-1217.